All News
Tofacitinib shows promise in scleroderma
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Read ArticleRheumNow Podcast – “That’s Not My Name” (10.7.2022)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Read ArticlePhysician Burnout Rising
The NY Times has reported results of a study showing that nearly two-thirds of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic. These findings suggest that burnout rates amongst US doctors have risen to alarming levels.
Read ArticleRheumatology Salaries and Career Choices
A recent doximity report shows how rheumatology salaries increase by years in practice. Their salary estimates are based on Doximity acquired data from over 200,000 physicians, along with publicly-available career and salary data from the U.S. Bureau of Labor Statistics, the U.S.
Read ArticleLinks:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/Vt25ui8GwF https://t.co/chKZt6dvaO
Links:
Links:
Links: